Iparomlimab
Neoadjuvant Chemoimmunotherapy
Sun Yat-sen UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Neoadjuvant Chemoimmunotherapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Epirubicin Shanghai Pulmonary Hospital, Shanghai, China | Phase 3 | B |
Docetaxel Shanghai Pulmonary Hospital, Shanghai, China | Phase 3 | B |
Capecitabine Sun Yat-sen University | Phase 2 | CCC |
PROPRANOLOL Sun Yat-sen University | Phase 2 | CCC |
Tuvonralimab Sun Yat-sen University | Phase 2 | CCC |
Eloxatin Sun Yat-sen University | Phase 2 | CCC |
Same molecule, other indications
Iparomlimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →